Targeting neoantigens to augment antitumour immunity von Yarchoan, Mark, Johnson, Burles A., Lutz, Eric R., Laheru, Daniel A., Jaffee, Elizabeth M.

Volltext

Targeting neoantigens to augment antitumour immunity von Yarchoan, Mark, Johnson, 3rd, Burles A, Lutz, Eric R, Laheru, Daniel A, Jaffee, Elizabeth M

Volltext

Strategies for Increasing Pancreatic Tumor Immunogenicity von Johnson, 3rd, Burles A, Yarchoan, Mark, Lee, Valerie, Laheru, Daniel A, Jaffee, Elizabeth M

Volltext

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase von Muller, Alexander J, Sharma, Madhav D, Chandler, Phillip R, DuHadaway, James B, Everhart, Mary E, Johnson, Burles A. III, Kahler, David J, Pihkala, Jeanene, Soler, Alejandro Peralta, Munn, David H, Prendergast, George C, Mellor, Andrew L

Volltext

Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model von Steinmetz, Alexis R, Pierce, Morgan, Martini, Alberto, Tholomier, Come, Manyam, Ganiraju, Chen, Yan, Sood, Akshay, Duplisea, Jonathan J, Johnson, Burles A, Czerniak, Bogdan A, Lee, Byron H, Jagannath, Chinnaswamy, Yla-Herttuala, Seppo, Parker, Nigel R, McConkey, David J, Dinney, Colin P, Mokkapati, Sharada

Volltext

Physiologic control of IDO competence in splenic dendritic cells von Baban, Babak, Chandler, Phillip R, Johnson, 3rd, Burles A, Huang, Lei, Li, Minghui, Sharpe, Marlon L, Francisco, Loise M, Sharpe, Arlene H, Blazar, Bruce R, Munn, David H, Mellor, Andrew L

Volltext

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer von Yarchoan, Mark, Myzak, Melinda C, Johnson, 3rd, Burles A, De Jesus-Acosta, Ana, Le, Dung T, Jaffee, Elizabeth M, Azad, Nilofer S, Donehower, Ross C, Zheng, Lei, Oberstein, Paul E, Fine, Robert L, Laheru, Daniel A, Goggins, Michael

Volltext

B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase von Johnson, Burles A. III, Kahler, David J, Baban, Babak, Chandler, Phillip R, Kang, Baolin, Shimoda, Michiko, Koni, Pandelakis A, Pihkala, Jeanene, Vilagos, Bojan, Busslinger, Meinrad, Munn, David H, Mellor, Andrew L

Volltext

Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder von Agrawal, Pranjal, Rostom, Mary, Alam, Ridwan, Florissi, Isabella, Biles, Michael, Rodriguez, Katherine, Hahn, Noah M, Johnson, 3rd, Burles A, Matoso, Andres, Smith, Armine, Bivalacqua, Trinity J, Kates, Max, Hoffman-Censits, Jeannie, Patel, Sunil H

Volltext

Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature von Aragaki, Adam K., Jing, Yuezhou, Hoffman-Censits, Jean, Choi, Woonyoung, Hahn, Noah M., Trock, Bruce J., McConkey, David J., Johnson, Burles A.

Volltext

Lentiviral interferon: A novel method for gene therapy in bladder cancer von Mokkapati, Sharada, Narayan, Vikram M., Manyam, Ganiraju C., Lim, Amy H., Duplisea, Jonathan J., Kokorovic, Andrea, Miest, Tanner S., Mitra, Anirban P., Plote, Devin, Anand, Selvalakshmi Selvaraj, Metcalfe, Michael J., Dunner, Kenneth, Johnson, Burles, Czerniak, Bogdan A., Nieminen, Tiina, Heikura, Tommi, Yla-Herttuala, Seppo, Parker, Nigel R., Schluns, Kimberley S., McConkey, David J., Dinney, Colin P.

Volltext

Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis von Johnson III, Burles A., Teply, Benjamin A., Kagemann, Catherine, McGuire, Bridget, Lombardo, Kara, Jing, Yuezhou, Langbo, William, Epstein, Jonathan I., Netto, George J., Baras, Alex S., Matoso, Andres, McConkey, David J., Gupta, Amol, Ahuja, Nita, Ross, Ashley E., Pierorazio, Phillip M., Comperat, Eva, Hoffman-Censits, Jean, Singla, Nirmish, Patel, Sunil H., Kates, Max, Choi, Woonyoung, Bivalacqua, Trinity J., Hahn, Noah M.

Volltext

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Ca... von Hahn, Noah M., O'Donnell, Michael A., Efstathiou, Jason A., Zahurak, Marianna, Rosner, Gary L., Smith, Jeff, Kates, Max R., Bivalacqua, Trinity J., Tran, Phuoc T., Song, Daniel Y., Baras, Alex S., Matoso, Andres, Choi, Woonyoung, Smith, Kellie N., Pardoll, Drew M., Marchionni, Luigi, McGuire, Bridget, Grace Phelan, Mary, Johnson, Burles A., O'Neal, Tanya, McConkey, David J., Rose, Tracy L., Bjurlin, Marc, Lim, Emerson A., Drake, Charles G., McKiernan, James M., Deutsch, Israel, Anderson, Christopher B., Lamm, Donald L., Geynisman, Daniel M., Plimack, Elizabeth R., Hallman, Mark A., Horwitz, Eric M., Al-Saleem, Essel, Chen, David Y.T., Greenberg, Richard E., Kutikov, Alexander, Guo, Gordon, Masterson, Timothy A., Adra, Nabil, Kaimakliotis, Hristos Z.

Volltext

pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer von Yarchoan, Mark, Ma, Changqing, Troxel, Andrea B., Stopenski, Stephen J., Tang, Waixing, Cohen, Aaron B., Pappas-Paxinos, Marina, Johnson, Burles A., Chen, Emerson Y., Feldman, Michael D., Brose, Marcia S.

Volltext

Erratum: Targeting neoantigens to augment antitumour immunity von Yarchoan, Mark, Johnson, Burles A., Lutz, Eric R., Laheru, Daniel A., Jaffee, Elizabeth M.

Volltext

Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience von Vlachou, Evangelia, Johnson, Burles Avner, McConkey, David, Jing, Yuezhou, Matoso, Andres, Hahn, Noah M, Hoffman-Censits, Jean

Volltext

Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer von Vlachou, Evangelia, Johnson, 3rd, Burles Avner, Baraban, Ezra, Nadal, Rosa, Hoffman-Censits, Jean

Volltext

Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin von Vlachou, Evangelia, Mamtani, Ronac, Hahn, Noah M., III, Burles Johnson, Hoffman-Censits, Jean, Nimgaonkar, Vivek

Volltext

Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience von Vlachou, Evangelia, Hahn, Noah M., Dabb, Alix, Johnson, Burles Avner, Lefande, M. Susan, Hoffman-Censits, Jean H.

Volltext

Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature von Vlachou, Evangelia, Matoso, Andres, McConkey, David, Jing, Yuezhou, Johnson, Burles Avner, Hahn, Noah M., Hoffman-Censits, Jean

Volltext